|
Net sales grew by marginal 0.1% year on year to Rs 200.53 crore in Q3 FY22 as compared to Rs 200.25 crore posted in Q3 FY21. Profit before tax fell 42.5% to Rs 16.26 crore in Q3 FY22 over Q3 FY21.
The drug maker's total expenditure spiked 9.6% to Rs 185.86 crore in Q3 FY22 from Rs 169.51 crore posted in the corresponding period last year.
In last three months, shares of AstraZeneca have fallen 7.9% as compared to a 4.4% decline in benchmark Nifty 50 index.
AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease.
AstraZeneca ended 0.56% lower at Rs 2,767.60 on Tuesday.
|